Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial
Authors' conclusion
The EMPACT-MI trial will establish the benefit and risks of empagliflozin treatment in patients with AMI.
Study context
- Population
- Patients with acute MI6,610 screened
- Participants
- 6,522 patients
- Comparison
- Empagliflozin vs placebo, in addition to standard of care
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Baseline characteristics
- Median age, years (IQR 56-71)
- 64
- Male
- 75.1%
- Hypertension
- 69.1%
- T2DM
- 31.7%
- Prior MI
- 13.0%
- AF
- 10.9%
- STEMI presentation
- 74.3%
- Acute signs or symptoms of congestion requiring treatment
- 56.9%
- LV systolic dysfunction with EF <45%
- 78.3%
Original publication
Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial. Eur J Heart Fail. Published 25 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →